丝氨酸
青霉素结合蛋白
抗生素
青霉素
微生物学
酶
生物
化学
生物化学
立体化学
计算生物学
作者
Andrew M. King,Dustin T. King,Shawn French,Éric Brouillette,Abdelhamid Asli,J. Andrew N. Alexander,Marija Vuckovic,Samarendra N. Maiti,Thomas R. Parr,Eric D. Brown,François Malouin,Natalie C. J. Strynadka,Gerard D. Wright
标识
DOI:10.1021/acschembio.5b00944
摘要
Avibactam is a diazabicyclooctane β-lactamase inhibitor possessing outstanding but incomplete efficacy against multidrug-resistant Gram-negative pathogens in combination with β-lactam antibiotics. Significant pharmaceutical investment in generating derivatives of avibactam warrants a thorough characterization of their activity. We show here through structural and kinetic analysis that select diazabicyclooctane derivatives display effective but varied inhibition of two clinically important β-lactamases (CTX-M-15 and OXA-48). Furthermore, these derivatives exhibit considerable antimicrobial activity (MIC ≤ 2 μg/mL) against clinical isolates of Pseudomonas aeruginosa, Escherichia coli, and Enterobacter spp. Imaging of cell phenotype along with structural and biochemical experiments unambiguously demonstrate that this activity, in E. coli, is a result of targeting penicillin-binding protein 2. Our results suggest that structure-activity relationship studies for the purpose of drug discovery must consider both β-lactamases and penicillin-binding proteins as targets. We believe that this approach will yield next-generation combination or monotherapies with an expanded spectrum of activity against currently untreatable Gram-negative pathogens.
科研通智能强力驱动
Strongly Powered by AbleSci AI